Pancreatic Cancer Research

ResearcherTUM KlinikumNo recent work listed

Zonera Hassan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7981-8328; OpenAlex author ID A5072922624. Sources: OpenAlex.

Their work

Papers
12 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
50
Papers, trials and grants by year

2017: 2 papers · 2018: 2 papers · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 5 papers

Papers 12

  1. Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition. First author DOI 10.1002/cac2.12280↗
  2. AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer. Co-author DOI 10.1007/s00018-022-04638-y↗
  3. HDAC2 Facilitates Pancreatic Cancer Metastasis. Co-author DOI 10.1158/0008-5472.can-20-3209↗
  4. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. Co-author DOI 10.1172/jci.insight.151353↗
  5. RelA Is an Essential Target for Enhancing Cellular Responses to the DNA Repair/Ref-1 Redox Signaling Protein and Restoring Perturbated Cellular Redox Homeostas… Co-author DOI 10.3389/fonc.2022.826617↗
  6. The SUMO pathway in pancreatic cancer: insights and inhibition. First author DOI 10.1038/s41416-020-01119-6↗
  7. Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. First author DOI 10.1002/1878-0261.12835↗
  8. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. First author DOI 10.1136/gutjnl-2018-317856↗
  9. MTOR inhibitor-based combination therapies for pancreatic cancer. Co-author DOI 10.1038/bjc.2017.421↗
  10. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Co-author DOI 10.1038/nature25459↗
  11. Role of CCL20 mediated immune cell recruitment in NF-κB mediated TRAIL resistance of pancreatic cancer. Co-author DOI 10.1016/j.bbamcr.2017.02.005↗
  12. HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer. First author DOI 10.1038/onc.2016.344↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Günter Schneider · 11 shared papers, 2017–2022 · strength 1.05
  2. Christian Schneeweis · 8 shared papers, 2018–2022 · strength 0.93
  3. Roland Rad · 9 shared papers, 2017–2022 · strength 0.82
  4. Dieter Saur · 9 shared papers, 2017–2022 · strength 0.82
  5. Maximilian Reichert · 8 shared papers, 2017–2022 · strength 0.77
  6. Matthias Wirth · 8 shared papers, 2017–2022 · strength 0.77
  7. Oliver Holger Krämer · 6 shared papers, 2017–2022 · strength 0.59
  8. Lukas Krauß · 4 shared papers, 2022 · strength 0.48
  9. Carolin Schneider · 4 shared papers, 2022 · strength 0.48
  10. Roland Michael Schmid · 5 shared papers, 2017–2022 · strength 0.39
  11. Ulrich Bernd Keller · 3 shared papers, 2020–2021 · strength 0.35
  12. Katharina Lankes · 3 shared papers, 2020–2022 · strength 0.32
  13. Felix Orben · 3 shared papers, 2020–2022 · strength 0.32
  14. Alexander Arlt · 4 shared papers, 2017–2022 · strength 0.30
  15. Wilko Weichert · 3 shared papers, 2018–2020 · strength 0.19
  16. Julia V. Mayerle · 2 shared papers, 2018–2022 · strength 0.16
  17. Melissa L. Fishel · 1 shared paper, 2022 · strength 0.15
  18. Mahmut Mijit · 1 shared paper, 2022 · strength 0.15
  19. Silpa Gampala · 1 shared paper, 2022 · strength 0.15
  20. Mark R. Kelley · 1 shared paper, 2022 · strength 0.15
  21. Zahra Dantes · 2 shared papers, 2018–2020 · strength 0.14
  22. Sandra Diersch · 1 shared paper, 2022 · strength 0.12
  23. Chiara Falcomatà · 1 shared paper, 2022 · strength 0.12
  24. Marian Grade · 1 shared paper, 2022 · strength 0.12
  25. Daniele Lucarelli · 1 shared paper, 2022 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.